Pulmonary administration of erythropoietin
US5354934A · kind A · utility
108Cited by
4References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 4, 1993 |
| Grant date | Oct 11, 1994 |
| Priority date | — |
| Expiry date | Feb 4, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P7/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Erythropoietin (EPO) can be delivered systemically in therapeutically or prophylactically effective amounts by pulmonary administration using a variety of pulmonary delivery devices, including nebulizers, metered dose inhalers and powder inhalers. Aerosol administration of EPO in accordance with this invention results in significant elevation of red blood cell levels. EPO can be administered in this manner to medically treat or prevent anemia, as well as to treat or prevent other maladies related to erythropoiesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.